HOUSTON – (July 1, 2009) – A low dose of oral interferon alpha shows promise in preserving beta cell function for patients with newly diagnosed type 1 diabetes, or juvenile diabetes, according to researchers at The University of Texas Medical School at Houston.
The results of the Phase II trial are published today in Diabetes Care, a journal of the American Diabetes Association.